Associations of BCL2 CA-Repeat Polymorphism and Breast Cancer Susceptibility in Isfahan Province of Iran

BCL2 apoptosis regulator ( BCL2 ) is a cause of tumorigenesis whose CA-repeat promoter polymorphisms has inconsistent association with various types of cancers. The association of BCL2 polymorphism with breast cancer was investigated in the Isfahan province of Iran. PCRamplification of the CA-repeat...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical genetics 2021-04, Vol.59 (2), p.506-515
Main Authors: Ghorbani, Fatemeh, Javadirad, Seyed-Morteza, Amirmahani, Farzane, Fatehi, Zahra, Tavassoli, Manoochehr
Format: Article
Language:English
Subjects:
Alleles
Apoptosis
Biochemistry
Biomedical and Life Sciences
Biomedicine
Breast cancer
Electrophoresis
ErbB-2 protein
Gel electrophoresis
Gene polymorphism
Genotypes
Health risks
Human Genetics
Medical Microbiology
Original Article
Polyacrylamide
Polymorphism
Sequences
Tumorigenesis
Zoology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BCL2 apoptosis regulator ( BCL2 ) is a cause of tumorigenesis whose CA-repeat promoter polymorphisms has inconsistent association with various types of cancers. The association of BCL2 polymorphism with breast cancer was investigated in the Isfahan province of Iran. PCRamplification of the CA-repeat was followed by polyacrylamide gel electrophoresis and direct sequencing for 120 breast cancer women and an equal number of corresponding healthy control individuals. Seven different alleles, ranging from 11 to 17 CA-repeats were observed. Short alleles with 11 to 14 repeats were protective (OR 0.363, P  = 0.001), but large alleles with 15 to 17 repeats were threatening against breast cancer development (OR 2.780, P  = 0.001). Accordingly, genotypes with large alleles showed a higher risk of breast cancer development (OR 3.400, P  = 0.004). ERS1\ERBB2 positive breast cancer patients, but not PGRpositive ones, showed protection against breast cancer (OR 0.405, OR 0.346 respectively). In conclusion, women with at least one large allele of BCL2 were 3.4 times at higher risk of breast cancer development in the Isfahan province of Iran.
ISSN:0006-2928
1573-4927
DOI:10.1007/s10528-020-10013-y